Xtant Medical (US:XTNT)2025-11-10 21:46Financial Performance - Total revenue for Q3 2025 was $33.3 million, representing a 19% increase year-over-year from $27.9 million in Q3 2024[6] - Net income for Q3 2025 was $1.3 million, compared to a net loss of $5.0 million in Q3 2024[8] - Adjusted EBITDA for Q3 2025 was $4.5 million, a significant improvement from an adjusted EBITDA loss of $1.0 million in Q3 2024[9] - Total revenue for the three months ended September 30, 2025, was $33.255 million, an increase from $27.937 million in the same period of 2024, representing a growth of 19.1%[23] - Product revenue for the nine months ended September 30, 2025, reached $87.492 million, compared to $85.754 million in 2024, showing a growth of 2.0%[23] - Net income for the nine months ended September 30, 2025, was $4.916 million, a significant recovery from a net loss of $13.284 million in the same period of 2024[25] - Non-GAAP Adjusted EBITDA for the nine months ended September 30, 2025, was $14.482 million, compared to a loss of $2.488 million in 2024[27] Cost Management - Gross margin improved to 66.1% in Q3 2025, up from 58.4% in the same period last year[7] - Operating expenses decreased to $19.5 million in Q3 2025, down from $20.1 million in Q3 2024[8] - Operating expenses decreased to $19.451 million for the three months ended September 30, 2025, from $20.084 million in 2024, a reduction of 3.2%[23] - The company experienced a significant reduction in loss from operations, reporting a loss of $2.541 million for the three months ended September 30, 2025, compared to a loss of $3.777 million in 2024[23] - Interest expense for the nine months ended September 30, 2025, was $2.953 million, a slight decrease from $3.026 million in 2024[27] Cash Flow and Liquidity - Cash generated from operations was $4.6 million in Q3 2025, compared to cash used in operations of $1.7 million in the prior year quarter[5] - As of September 30, 2025, cash and cash equivalents increased to $10.6 million from $6.2 million at the end of 2024[11] - Cash and cash equivalents at the end of the nine months ended September 30, 2025, totaled $10.641 million, up from $7.086 million in 2024[25] - The company reported a net cash provided by operating activities of $7.166 million for the nine months ended September 30, 2025, compared to a net cash used of $12.561 million in 2024[25] Strategic Initiatives - The company reiterated its full-year 2025 revenue guidance of $131-$135 million, indicating growth of 11%-15% over FY24[12] - The anticipated sale of non-core assets and international businesses to Companion Spine is expected to close by year-end 2025[5] - The company launched CollagenX™, a new bovine collagen particulate product aimed at enhancing surgical wound closure[5]